HansBiomed Corporation (KOSDAQ:042520)
South Korea · Delayed Price · Currency is KRW 31,300
+1,450 (4.86%)
At close: Apr 10, 2026
HansBiomed Revenue
HansBiomed had revenue of 30.27B KRW in the quarter ending December 31, 2025, with 52.27% growth. This brings the company's revenue in the last twelve months to 100.17B, up 24.20% year-over-year. In the fiscal year ending September 30, 2025, HansBiomed had annual revenue of 89.78B with 10.65% growth.
Revenue (ttm)
100.17B
Revenue Growth
+24.20%
P/S Ratio
4.46
Revenue / Employee
337.27M
Employees
297
Market Cap
446.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Sep 30, 2025 | 89.78B | 8.64B | 10.65% |
| Sep 30, 2024 | 81.14B | 3.11B | 3.98% |
| Sep 30, 2023 | 78.03B | 3.57B | 4.80% |
| Sep 30, 2022 | 74.46B | 15.36B | 25.99% |
| Sep 30, 2021 | 59.10B | -21.00B | -26.22% |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| NIBEC | 32.72B |
| S.Biomedics | 16.55B |
| Bio Solution | 15.20B |
| TiumBio | 12.29B |
| Kangstem Biotech | 3.57B |
| Y-Biologics | 2.91B |
| IntoCell | 2.30B |
| curacle co.,ltd. | 7.10M |